OncLive

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer | OncLive RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

RAD51-Based HRD Test Could Help Refine Patient Selection for Olaparib in BRCA1/2- or PALB2-Mutant, HER2– Breast Cancer #SABCS2025 #bcsm #oncology www.onclive.com/view/rad51-b...

Sacituzumab Govitecian Plus Pembrolizumab Yields Predicticable, Manageable Safety Profile in TNBC | OncLive Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

Sacituzumab Govitecian Plus Pembrolizumab Yields Predicticable, Manageable Safety Profile in TNBC
@sabcs.bsky.social #SABCS25 #bcsm #oncology
www.onclive.com/view/sacituz...

BREAKING 🚨: @fda.gov Approves Niraparib/Abiraterone Acetate Plus Prednisone for BRCA2+ mCSPC

Learn more here 📰: www.onclive.com/view/fda-app...

#blcsm #oncology #FDAapproved

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC | OncLive MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

MRD Detection With Novel ctDNA Assay Helps Determine Distant Recurrence Risk in TNBC
@sabcs.bsky.social #SABCS25 #bcsm #oncology
www.onclive.com/view/mrd-det...

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML | OncLive TERN-701 yielded a high response rate with deep molecular responses in heavily pretreated chronic phase chronic myeloid leukemia.

TERN-701 Elicits Deep Responses in Heavily Pretreated CP-CML @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #oncology www.onclive.com/view/tern-70...

Phase 3 STAR-221 Study of First-Line Domvanalimab/Zimberelimab Plus Chemo in Upper GI Cancers to Be Discontinued | OncLive Both the phase 3 STAR-221 trial and phase 2 EDGE-Gastric studies of domvanalimab plus zimberelimab in upper GI cancers are being discontinued.

Phase 3 STAR-221 Study of First-Line Domvanalimab/Zimberelimab Plus Chemo in Upper GI Cancers to Be Discontinued #oncology www.onclive.com/view/phase-3...

Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer | OncLive Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

Gedatolisib Plus Fulvestrant ± Palbociclib Is a Potential New SOC in HR+ PIK3CA Wild-Type Advanced Breast Cancer
@sabcs.bsky.social #SABCS25 #oncology #bcsm
www.onclive.com/view/gedatol...

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer | OncLive An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Long-Term PALLAS Data Show No Adjusted OS Difference With Adjuvant Palbociclib in HR+/HER2– Breast Cancer #SABCS2025 #bcsm #oncology www.onclive.com/view/long-te...

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer | OncLive Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Camizestrant Switch Plus CDK4/6 Inhibition Continues to Outperform SOC in HR+/HER2– Breast Cancer @institutcurie.bsky.social @sabcs.bsky.social #SABCS25 #bcsm #oncology www.onclive.com/view/camizes...

Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer | OncLive Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Elacestrant-Based Combinations Show Efficacy, Safety in ER+, HER2-Negative Breast Cancer @sabcs.bsky.social #SABCS25 #bcsm
www.onclive.com/view/elacest...

CAPItello-291 Analysis Reveals Potential Utility of PIK3CA/AKT1/PTEN Alteration Detection Via ctDNA in Advanced HR+ Breast Cancer | OncLive Circulating tumor DNA could represent a minimally invasive approach for detecting AKT pathway alterations in hormone receptor–positive breast cancer.

CAPItello-291 Analysis Reveals Potential Utility of PIK3CA/AKT1/PTEN Alteration Detection Via ctDNA in Advanced HR+ Breast Cancer @sabcs.bsky.social #SABCS25 www.onclive.com/view/capitel...

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC | OncLive Pembrolizumab in the adjuvant setting yielded high DFS and OS results in addition to a manageable safety profile in real-world patients with ccRCC.

Real-World Data Showcase Efficacy of Adjuvant Pembrolizumab in ccRCC #ESMO25 #kcsm #oncology www.onclive.com/view/real-wo...

Resection of MRI-Detected Disease Fails to Improve Recurrence Rates in Early Breast Cancer | OncLive Locoregional recurrence-free rates were similar in newly diagnosed breast cancer, irrespective of resection of MRI-detected disease.

Resection of MRI-Detected Disease Fails to Improve Recurrence Rates in Early Breast Cancer @sabcsss.bsky.social #SABCS2025 #bcsm #oncology www.onclive.com/view/resecti...

Belzutifan Maintains Efficacy After a PD-(L)1 Inhibitor and Multiple VEGFR TKIs in ccRCC | OncLive Belzutifan maintained efficacy benefits vs everolimus among patients with ccRCC after at least 2 prior VEGFR TKIs.

Belzutifan Maintains Efficacy After a PD-(L)1 Inhibitor and Multiple VEGFR TKIs in ccRCC
#kcsm #oncology
www.onclive.com/view/belzuti...

T-DXd Displays iDFS Benefit in Key Subgroups of HER2+ Early Breast Cancer With Residual Invasive Disease | OncLive T-DXd yielded iDFS improvements in HER2-positive early breast cancer with residual invasive disease, irrespective of HER2 expression of neoadjuvant chemotherapy type.

T-DXd Displays iDFS Benefit in Key Subgroups of HER2+ Early Breast Cancer With Residual Invasive Disease @sabcs.bsky.social #SABCS25 #bcsm #oncology www.onclive.com/view/t-dxd-d...

Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer | OncLive Tucatinib plus HP improved median investigator-assessed PFS by 8.6 months as first-line maintenance vs HP alone in HER2-positive metastatic breast cancer.

Maintenance Tucatinib Plus HP Extends Median PFS Beyond 2 Years in Advanced HER2+ Breast Cancer @erikahamilton9.bsky.social @sabcs.bsky.social #SABCS25 #bcsm #oncology www.onclive.com/view/mainten...

Trastuzumab Deruxtecan Plus Pertuzumab Does Not Worsen QOL in HER2+ Metastatic Breast Cancer | OncLive Frontline treatment with T-DXd plus pertuzumab improved QOL vs THP in patients with HER2-positive advanced or metastatic breast cancer.

Trastuzumab Deruxtecan Plus Pertuzumab Does Not Worsen QOL in HER2+ Metastatic Breast Cancer @sabcs.bsky.social @bcmhouston.bsky.social #SABCS25 www.onclive.com/view/trastuz...

Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC | OncLive PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.

Sacituzumab Govitecan Maintains QOL Benefit Over Chemotherapy in Previously Untreated TNBC @sabcs.bsky.social #SABCS2025 #bcsm
www.onclive.com/view/sacituz...

Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer | OncLive The multimodal ICM+ model was prognostic for long-term recurrence following treatment in early breast cancer.

Multimodal AI Model Prognostic for Long-Term Recurrence Following Treatment for Early Breast Cancer @sabcs.bsky.social @mountsinainyc.bsky.social
#SABCS25 #bcsm www.onclive.com/view/multimo...

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer | OncLive Abemaciclib monotherapy displayed a clinical benefit in some patients with HR+/HER2– breast cancer after CDK4/6 inhibitor therapy.

Abemaciclib Monotherapy Shows Efficacy After CDK4/6 Inhibition in HR+/HER2– Breast Cancer @sabcs.bsky.social #SABC25 www.onclive.com/view/abemaci...

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer | OncLive OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Giredestrant Improves iDFS Compared With Endocrine Therapy in ER+, HER2– Breast Cancer @sabcs.bsky.social @uclahealth.org #SABCS25 #bcsm www.onclive.com/view/giredes...

Dr Arora on Azacitidine Plus Venetoclax and Gilteritinib in FLT3 Wild-Type AML | OncLive Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.

WATCH: Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia. @mdanderson.bsky.social @ash.hematology.org #ASH25 #leusm #hematology
www.onclive.com/view/dr-aror...

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer | OncLive Adjuvant AI therapy improved DFS and TTDR vs a SERM in patients with hormone receptor–positive, HER2-positive early breast cancer.

Adjuvant Aromatase Inhibition Is Associated With Improved DFS, TTDR in HR+/HER2+ Breast Cancer @sabcs.bsky.social #SABCS25 www.onclive.com/view/adjuvan...

AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis | OncLive AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis #oncology #hematology
www.onclive.com/view/aj1-110...

Orca-Q Yields Low Rates of GVHD and Non-Relapse Mortality in High-Risk Hematologic Malignancies | OncLive Myeloablative Orca-Q demonstrated efficacy and safety in high-risk hematologic malignancies.

Orca-Q Yields Low Rates of GVHD and Non-Relapse Mortality in High-Risk Hematologic Malignancies
@ash.hematology.org @mdanderson.bsky.social #ASH25 #leusm #lymsm #oncology
www.onclive.com/view/orca-q-...

Axi-Cel Is Safe and Effective in Real-World R/R Follicular Lymphoma | OncLive Axi-cel led to durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Axi-Cel Is Safe and Effective in Real-World R/R Follicular Lymphoma @kuhospital.bsky.social @ash.hematology.org #ASH25 #lymsm #hematology www.onclive.com/view/axi-cel...

Dr Kamdar on the Long-Term Efficacy of Liso-Cel in R/R LBCL | OncLive Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.

WATCH: Manali Kamdar, MD, discusses the long-term efficacy findings with lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. @cucancercenter.bsky.social @ash.hematology.org #ASH25 #lymsm #hematology
www.onclive.com/view/dr-kamd...

Hear @fadihaddadmd.bsky.social, of @mdanderson.bsky.social, preview insights on phase 2 results with asciminib in patients with newly diagnosed CML, which were presented at #ASH25! See more from Dr Haddad and beyond on our site. @ash.hematology.org #leusm #Hematology
www.onclive.com/conference/ash

A huge thanks to Dr John Burke for sitting down with us at #ASH25 to highlight findings from the MorningSun study of mosunetuzumab in follicular lymphoma! Check out our site for exclusive #lymsm coverage and more from the meeting. @ash.hematology.org
www.onclive.com/conference/ash

Thanks to Dr David Siegel of @hackensackmeridianhealth.org for stopping by at #ASH25 to discuss real-world data with talquetamab or elranatamab with pomalidomide in myeloma! See our site for more from the meeting. @ash.hematology.org #mmsm #hematology
www.onclive.com/conference/ash